Why DuPont chose joint-venture
DuPont explained its rationale for the sale in a Sept. 11 presentation to New York analysts. "The problem is we didn't have the marketing expertise or the ability to get the things through regulatory systems around the world. We didn't have a strong system. The choice was either sell the business, make a big acquisition or find an alliance. And our conclusion was we could maximize stock holder value by not making a big acquisition and all the risk that goes with that. We did not think that we could sell the business for any significant pay off for the shareholders and we were just very thrilled that we were able to entice Merck, who we consider the outstanding pharmaceutical company in the world".
You may also be interested in...
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.